MODERNA INC (1MRNA.MI) Stock Fundamental Analysis
Europe - BIT:1MRNA - US60770K1079 - Common Stock
23.525 EUR
+0.5 (+2.19%)
Overall 1MRNA gets a fundamental rating of 3 out of 10. We evaluated 1MRNA against 76 industry peers in the Biotechnology industry. The financial health of 1MRNA is average, but there are quite some concerns on its profitability. 1MRNA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1MRNA has reported negative net income.
1MRNA had a negative operating cash flow in the past year.
In multiple years 1MRNA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: 1MRNA reported negative operating cash flow in multiple years.
1.2 Ratios
1MRNA has a Return On Assets (-24.17%) which is comparable to the rest of the industry.
1MRNA's Return On Equity of -30.89% is fine compared to the rest of the industry. 1MRNA outperforms 67.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.17% | ||
| ROE | -30.89% | ||
| ROIC | N/A |
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 68.32%, 1MRNA is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
1MRNA's Gross Margin has declined in the last couple of years.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1MRNA has been increased compared to 1 year ago.
The number of shares outstanding for 1MRNA has been increased compared to 5 years ago.
Compared to 1 year ago, 1MRNA has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.35 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.35, 1MRNA is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that 1MRNA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, 1MRNA belongs to the top of the industry, outperforming 85.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.35 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
1MRNA has a Current Ratio of 3.93. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 1MRNA (3.93) is better than 69.74% of its industry peers.
A Quick Ratio of 3.77 indicates that 1MRNA has no problem at all paying its short term obligations.
1MRNA's Quick ratio of 3.77 is fine compared to the rest of the industry. 1MRNA outperforms 72.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.77 |
3. Growth
3.1 Past
1MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.04%, which is quite impressive.
1MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.05%.
The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%
3.2 Future
The Earnings Per Share is expected to grow by 18.29% on average over the next years. This is quite good.
1MRNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.42% yearly.
EPS Next Y-7.04%
EPS Next 2Y6.85%
EPS Next 3Y12.27%
EPS Next 5Y18.29%
Revenue Next Year-41.12%
Revenue Next 2Y-19.11%
Revenue Next 3Y-6.55%
Revenue Next 5Y18.42%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
Also next year 1MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
1MRNA's earnings are expected to grow with 12.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y12.27%
5. Dividend
5.1 Amount
No dividends for 1MRNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1MRNA (10/31/2025, 7:00:00 PM)
23.525
+0.5 (+2.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.95%
Inst Owner ChangeN/A
Ins Owners2.55%
Ins Owner ChangeN/A
Market Cap9.19B
Revenue(TTM)3.08B
Net Income(TTM)-2903000000
Analysts55.33
Price Target38.27 (62.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.41%
Min EPS beat(2)21.22%
Max EPS beat(2)29.6%
EPS beat(4)3
Avg EPS beat(4)36.52%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-7.95%
EPS beat(12)8
Avg EPS beat(12)0.84%
EPS beat(16)11
Avg EPS beat(16)4.98%
Revenue beat(2)1
Avg Revenue beat(2)11.48%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)17.36%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)46.04%
Revenue beat(8)7
Avg Revenue beat(8)31.8%
Revenue beat(12)9
Avg Revenue beat(12)25.64%
Revenue beat(16)12
Avg Revenue beat(16)20.85%
PT rev (1m)-3.86%
PT rev (3m)-10.3%
EPS NQ rev (1m)-1.97%
EPS NQ rev (3m)-12.2%
EPS NY rev (1m)0.45%
EPS NY rev (3m)3.93%
Revenue NQ rev (1m)-2.17%
Revenue NQ rev (3m)-24.07%
Revenue NY rev (1m)-1.48%
Revenue NY rev (3m)-9.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.13 | ||
| P/tB | 1.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.52
EYN/A
EPS(NY)-6.89
Fwd EYN/A
FCF(TTM)-7.76
FCFYN/A
OCF(TTM)-5.98
OCFYN/A
SpS6.82
BVpS20.83
TBVpS20.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.17% | ||
| ROE | -30.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.32% | ||
| FCFM | N/A |
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score4
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 386.06% | ||
| Cap/Sales | 26.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.77 | ||
| Altman-Z | 3.35 |
F-Score4
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
EPS Next Y-7.04%
EPS Next 2Y6.85%
EPS Next 3Y12.27%
EPS Next 5Y18.29%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%
Revenue Next Year-41.12%
Revenue Next 2Y-19.11%
Revenue Next 3Y-6.55%
Revenue Next 5Y18.42%
EBIT growth 1Y35.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.33%
EBIT Next 3Y14.92%
EBIT Next 5Y18.54%
FCF growth 1Y-364.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1093.36%
OCF growth 3YN/A
OCF growth 5YN/A
MODERNA INC / 1MRNA.MI FAQ
Can you provide the ChartMill fundamental rating for MODERNA INC?
ChartMill assigns a fundamental rating of 3 / 10 to 1MRNA.MI.
What is the valuation status of MODERNA INC (1MRNA.MI) stock?
ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (1MRNA.MI). This can be considered as Overvalued.
Can you provide the profitability details for MODERNA INC?
MODERNA INC (1MRNA.MI) has a profitability rating of 2 / 10.
What is the expected EPS growth for MODERNA INC (1MRNA.MI) stock?
The Earnings per Share (EPS) of MODERNA INC (1MRNA.MI) is expected to decline by -7.04% in the next year.